Countering emerging Sars-CoV-2 variants
Recorded event – May 5, 2021
The global COVID-19 pandemic created an urgent need for protective interventions. With SARS-CoV-2 continuing to evolve, multiple approaches will likely be required to combat new viral variants as the scientific and pharmaceutical communities continue to develop anti-SARS-CoV-2 therapeutics and vaccines.
In this webinar, Dr. Jesse Erasmus from the University of Washington School of Medicine discusses his approach and how he mitigated key design and discovery hurdles to designing a framework for the scalable manufacturing and improved stability required for global vaccine distribution. Dr. Erasmus will further discuss his development of a two-vialed replicating RNA (repRNA) vaccine and Lipid InOrganic Nanoparticle (LION) platform that can be mixed immediately before injection.
Jesse Erasmus, PhD. is an Acting Assistant Professor at the University of Washington School of Medicine and the Director of Virology at HDT Bio. His research focuses on studying virus-derived mechanisms of gene expression for the development of new RNA vaccines and therapeutic technologies.